|4Jul 7, 6:47 AM ET

Dova Pharmaceuticals, Inc. 4

4 · Dova Pharmaceuticals, Inc. · Filed Jul 7, 2017

Insider Transaction Report

Form 4
Period: 2017-07-05
Laliberte Kevin
Sr. VP, Product Development
Transactions
  • Purchase

    Common Stock

    2017-07-05$17.00/sh+6,200$105,4006,200 total

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION